IPSCs: A Minireview from bench to bed, including organoids and the crispr system

Stem Cells International

Volumn 2016, Issue , 2016, Pages

  Orqueda, Andrés Javier ^a   Giménez, Carla Alejandra ^a   Pereyra Bonnet, Federico ^a  

^a Instituto Universitario del Hospital Italiano   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

KRUPPEL LIKE FACTOR 4; MESSENGER RNA; MYC PROTEIN; OCTAMER TRANSCRIPTION FACTOR 4; PLASMID VECTOR; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SOX2;

BRAIN; CELL DIFFERENTIATION; CELL REPROGRAMMING TECHNIQUE; CELL THERAPY; CRISPR CAS SYSTEM; CYTOPLASM; DNA METHYLATION; EMBRYONIC STEM CELL; EYE; GENE EXPRESSION; HEART; HUMAN; INTESTINE; LIVER; LUNG; MINIORGANOID; NONHUMAN; NUCLEAR REPROGRAMMING; PILOT STUDY; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SINGLE CELL ANALYSIS; STOMACH; UPREGULATION;

EID: 84955445987     PISSN: None     EISSN: 16879678     Source Type: Journal    
DOI: 10.1155/2016/5934782     Document Type: Review

References (68)

1. J.A. Thomson, J. Itskovitz-Eldor, S. S. Shapiroet al., "Embryonic stem cell lines derived from human blastocysts, " Science, vol. 282, no. 5391, pp. 1145-1147, 1998.
2. L. A. Boyer, T. I. Lee, M. F. Cole et al., "Core transcriptional regulatory circuitry in human embryonic stem cells, " Cell, vol. 122, no. 6, pp. 947-956, 2005.
3. K. Takahashi and S. Yamanaka, "Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors, " Cell, vol. 126, no. 4, pp. 663-676, 2006.
4. K. Takahashi, K. Tanabe, M. Ohnuki et al., "Induction of pluripotent stem cells from adult human fibroblasts by defined factors, " Cell, vol. 131, no. 5, pp. 861-872, 2007.
5. K. Hochedlinger and K. Plath, "Epigenetic reprogramming and induced pluripotency, " Development, vol. 136, no. 4, pp. 509-523, 2009.
6. S. Cawley, S. Bekiranov, H. H. Ng et al., "Unbiased mapping of transcription factor binding sites along human chromosomes 21 and 22 points to widespread regulation of noncoding RNAs, " Cell, vol. 116, no. 4, pp. 499-509, 2004.
7. S. B. McMahon, H. A. Van Buskirk, K. A. Dugan, T. D. Copeland, and M. D. Cole, "The novel ATM-related protein TRRAP is an essential cofactor for the c-Myc and E2F oncoproteins, " Cell, vol. 94, no. 3, pp. 363-374, 1998.
8. Y. Li, H. Zhao, F. Lan et al., "Generation of human-induced pluripotent stem cells from gut mesentery-derived cells by ectopic expression of OCT4/SOX2/NANOG, " Cellular Reprogramming, vol. 12, no. 3, pp. 237-247, 2010.
9. D. Huangfu, K. Osafune, R. Maehr et al., "Induction of pluripotent stem cells from primary human fibroblasts with only Oct4 and Sox2, " Nature Biotechnology, vol. 26, no. 11, pp. 1269-1275, 2008.
10. F. Jia, K. D. Wilson, N. Sun et al., "A nonviral minicircle vector for deriving human iPS cells, " Nature Methods, vol. 7, no. 3, pp. 197-199, 2010.
11. E. Yakubov, G. Rechavi, S. Rozenblatt, and D. Givol, "Reprogramming of human fibroblasts to pluripotent stem cells using mRNA of four transcription factors, " Biochemical and Biophysical Research Communications, vol. 394, no. 1, pp. 189-193, 2010.
12. Y. Li, Q. Zhang, X. Yin et al., "Generation of iPSCs from mouse fibroblasts with a single gene, Oct4, and small molecules, " Cell Research, vol. 21, no. 1, pp. 196-204, 2011.
13. S. M. Wu and K. Hochedlinger, "Harnessing the potential of induced pluripotent stem cells for regenerative medicine, " Nature Cell Biology, vol. 13, no. 5, pp. 497-505, 2011.
14. P. Hou, Y. Li, X. Zhang et al., "Pluripotent stem cells induced from mouse somatic cells by small-molecule compounds, " Science, vol. 341, no. 6146, pp. 651-654, 2013.
15. J. Vrbsky, T. Tereh, S. Kyrylenko, P. Dvorak, L. Krejci, and M. Lako, "MEK and TGF-beta inhibition promotes reprogramming without the use of transcription factor, " PLoS ONE, vol. 10, no. 6, Article ID e0127739, 2015.
16. Y. Rais, A. Zviran, S. Geula et al., "Deterministic direct reprogramming of somatic cells to pluripotency, " Nature, vol. 502, no. 7469, pp. 65-70, 2013.
17. J. Yu, M. A. Vodyanik, K. Smuga-Otto et al., "Induced pluripotent stem cell lines derived from human somatic cells, " Science, vol. 318, no. 5858, pp. 1917-1920, 2007.
18. J. Itskovitz-Eldor, M. Schuldiner, D. Karsenti et al., "Differentiation of human embryonic stem cells into embryoid bodies compromising the three embryonic germ layers, " Molecular Medicine, vol. 6, no. 2, pp. 88-95, 2000.
19. C. B. Fagundez, M. A. Loresi, M. E. Ojea Quintana et al., "A simple approach for mouse embryonic stem cells isolation and differentiation inducing embryoid body formation, " Cell Biology International, vol. 33, no. 11, pp. 1196-1200, 2009.
20. K. Okita, T. Ichisaka, and S. Yamanaka, "Generation of germline-competent induced pluripotent stem cells, " Nature, vol. 448, no. 7151, pp. 313-317, 2007.
21. M. H. Chin, M. J. Mason, W. Xie et al., "Induced pluripotent stem cells and embryonic stem cells are distinguished by gene expression signatures, " Cell Stem Cell, vol. 5, no. 1, pp. 111-123, 2009.
22. R. Lister, M. Pelizzola, Y. S. Kida et al., "Hotspots of aberrant epigenomic reprogramming in human induced pluripotent stem cells, " Nature, vol. 471, no. 7336, pp. 68-73, 2011.
23. C. Bock, E. Kiskinis, G. Verstappen et al., "Reference maps of human ES and iPS cell variation enable high-throughput characterization of pluripotent cell lines, " Cell, vol. 144, no. 3, pp. 439-452, 2011.
24. K. Kim, A. Doi, B. Wen et al., "Epigenetic memory in induced pluripotent stem cells, " Nature, vol. 467, no. 7313, pp. 285-290, 2010.
25. K.W. McCracken, E. M. Cata, C. M. Crawford et al., "Modelling human development and disease in pluripotent stem-cellderived gastric organoids, " Nature, vol. 516, no. 7531, pp. 400-404, 2014.
26. J. R. Spence, C. N. Mayhew, S. A. Rankin et al., "Directed differentiation of human pluripotent stem cells into intestinal tissue in vitro, " Nature, vol. 470, no. 7332, pp. 105-109, 2011.
27. J. L. Forbester, D. Goulding, L. Vallier et al., "Interaction of Salmonella enterica serovar typhimurium with intestinal organoids derived fromhuman induced pluripotent stemcells, " Infection and Immunity, vol. 83, no. 7, pp. 2926-2934, 2015.
28. B. R. Dye, D. R. Hill, M. A. Ferguson et al., "In vitro generation of human pluripotent stem cell derived lung organoids, " Elife, vol. 24, article 4, 2015.
29. T. Takebe, K. Sekine, M. Enomura et al., "Vascularized and functional human liver from an iPSC-derived organ bud transplant, " Nature, vol. 499, no. 7459, pp. 481-484, 2013.
30. M. A. Lancaster, M. Renner, C.-A. Martin et al., "Cerebral organoidsmodel human brain development and microcephaly, " Nature, vol. 501, no. 7467, pp. 373-379, 2013.
31. M. A. Lancaster and J. A. Knoblich, "Generation of cerebral organoids fromhuman pluripotent stemcells, " Nature Protocols, vol. 9, no. 10, pp. 2329-2340, 2014.
32. T.-Y. Lu, B. Lin, J. Kim et al., "Repopulation of decellularized mouse heart with human induced pluripotent stemcell-derived cardiovascular progenitor cells, "Nature Communications, vol. 4, article 2307, 2013.
33. M. J. Phillips, K. A. Wallace, S. J. Dickerson et al., "Bloodderived human iPS cells generate optic vesicle-like structures with the capacity to formretinal laminae and develop synapses, " Investigative Ophthalmology &Visual Science, vol. 53, no. 4, pp. 2007-2019, 2012.
34. M. J. Phillips, E. T. Perez, J. M. Martin et al., "Modeling human retinal development with patient-specific induced pluripotent stem cells reveals multiple roles for visual system homeobox 2, " Stem Cells, vol. 32, no. 6, pp. 1480-1492, 2014.
35. Z. Alipio, W. Liao, E. J. Roemer et al., "Reversal of hyperglycemia in diabetic mouse models using induced-pluripotent stem (iPS)-derived pancreatic -like cells, " Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 30, pp. 13426-13431, 2010.
36. D. Xu, Z. Alipio, L. M. Fink et al., "Phenotypic correction of murine hemophilia A using an iPS cell-based therapy, " Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 3, pp. 808-813, 2009.
37. O. Tsuji, K. Miura, Y. Okada et al., "Therapeutic potential of appropriately evaluated safe-induced pluripotent stem cells for spinal cord injury, " Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 28, pp. 12704-12709, 2010.
38. G. Hargus, O. Cooper, M. Deleidi et al., "Differentiated Parkinson patient-derived induced pluripotent stem cells grow in the adult rodent brain and reduce motor asymmetry in Parkinsonian rats, " Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 36, pp. 15921-15926, 2010.
39. J. Hanna, M. Wernig, S. Markoulaki et al., "Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin, " Science, vol. 318, no. 5858, pp. 1920-1923, 2007.
40. F. W. Pagliuca, J. R. Millman, M. Gurtler et al., "Generation of functional human pancreatic cells in vitro, " Cell, vol. 159, no. 2, pp. 428-439, 2014.
41. K. Tateishi, J. He, O. Taranova, G. Liang, A. C. D'Alessio, and Y. Zhang, "Generation of insulin-secreting islet-like clusters from human skinfibroblasts, "The Journal of Biological Chemistry, vol. 283, no. 46, pp. 31601-31607, 2008.
42. R. Maehr, S. Chen, M. Snitow et al., "Generation of pluripotent stem cells from patients with type 1 diabetes, " Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 37, pp. 15768-15773, 2009.
43. P. Mali, B.-K. Chou, J. Yen et al., "Butyrate greatly enhances derivation of human induced pluripotent stemcells by promoting epigenetic remodeling and the expression of pluripotencyassociated genes, " STEMCELLS, vol. 28, no. 4, pp.713-720, 2010.
44. K. Si-Tayeb, F. K. Noto, A. Sepac et al., "Generation of human induced pluripotent stem cells by simple transient transfection of plasmid DNA encoding reprogramming factors, " BMC Developmental Biology, vol. 10, article 81, 2010.
45. D. E. Buchholz, S. T. Hikita, T. J. Rowland et al., "Derivation of functional retinal pigmented epithelium frominduced pluripotent stem cells, " Stem Cells, vol. 27, no. 10, pp. 2427-2434, 2009.
46. L. Ye, J. C. Chang, C. Lin, X. Sun, J. Yu, and Y. W. Kan, "Induced pluripotent stem cells offer new approach to therapy in thalassemia and sickle cell anemia and option in prenatal diagnosis in genetic diseases, " Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 24, pp. 9826-9830, 2009.
47. J.R. Plews, J. Li, M. Jones et al., "Activation of pluripotency genes in human fibroblast cells by a novel mRNA based approach, " PLoS ONE, vol. 5, no. 12, Article IDe14397, 2010.
48. S. Karumbayaram, B. G. Novitch, M. Patterson et al., "Directed differentiation of human-induced pluripotent stem cells generates active motor neurons, " StemCells, vol. 27, no. 4, pp. 806-811, 2009.
49. F. Osakada, H. Ikeda, M. Mandai et al., "Toward the generation of rod and cone photoreceptors from mouse, monkey and human embryonic stem cells, " Nature Biotechnology, vol. 26, no. 2, pp. 215-224, 2008.
50. H. Kamao, M. Mandai, S. Okamoto et al., "Characterization of human induced pluripotent stem cell-derived retinal pigment epithelium cell sheets aiming for clinical application, " Stem Cell Reports, vol. 2, no. 2, pp. 205-218, 2014.
51. S. Okamoto and M. Takahashi, "Induction of retinal pigment epithelial cells from monkey iPS cells, " Investigative Ophthalmology and Visual Science, vol. 52, no. 12, pp. 8785-8790, 2011.
52. H. Kanemura, M. J. Go, M. Shikamura et al., "Tumorigenicity studies of induced pluripotent stem cell (iPSC)-derived retinal pigment epithelium (RPE) for the treatment of age-related macular degeneration, " PLoS ONE, vol. 9, no. 1, Article ID e85336, 2014.
53. A. Coghlan, "Unexpectedmutations put stemcell trial on hold, " New Scientist, vol. 227, no. 3033, p. 9, 2015.
54. I. Gunaseeli, M. X. Doss, C. Antzelevitch, J. Hescheler, and A. Sachinidis, "Induced pluripotent stem cells as a model for accelerated patient-And disease-specific drug discovery, " Current Medicinal Chemistry, vol. 17, no. 8, pp. 759-766, 2010.
55. K. Musunuru, "Genome editing of human pluripotent stemcells to generate human cellular disease models, " DiseaseModels and Mechanisms, vol. 6, no. 4, pp. 896-904, 2013.
56. B. Grobarczyk, B. Franco, K. Hanon, and B. Malgrange, "Generation of isogenic human iPS cell line precisely corrected by genome editing using the CRISPR/Cas9 system, " Stem Cell Reviews and Reports, vol. 11, no. 5, pp. 774-787, 2015.
57. R. Barrangou, C. Fremaux, H. Deveau et al., "CRISPR provides acquired resistance against viruses in prokaryotes, " Science, vol. 315, no. 5819, pp. 1709-1712, 2007.
58. M. Jinek, K. Chylinski, I. Fonfara, M. Hauer, J. A. Doudna, and E. Charpentier, "A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity, " Science, vol. 337, no. 6096, pp. 816-821, 2012.
59. P. Mali, L. Yang, K. M. Esvelt et al., "RNA-guided human genome engineering via Cas9, " Science, vol. 339, no. 6121, pp. 823-826, 2013.
60. F. A. Ran, P. D. Hsu, J. Wright, V. Agarwala, D. A. Scott, and F. Zhang, "Genome engineering using the CRISPR-Cas9 system, " Nature Protocols, vol. 8, no. 11, pp. 2281-2308, 2013.
61. M. L. De Groote, P. J. Verschure, and M. G. Rots, "Epigenetic editing: targeted rewriting of epigenetic marks to modulate expression of selected target genes, " Nucleic Acids Research, vol. 40, no. 21, pp. 10596-10613, 2012.
62. L. Cong, F. A. Ran, D. Cox et al., "Multiplex genome engineering using CRISPR/Cas systems, " Science, vol. 339, no. 6121, pp. 819-823, 2013.
63. C. Baum, C. von Kalle, F. J. T. Staal et al., "Chance or necessity? Insertional mutagenesis in gene therapy and its consequences, " MolecularTherapy, vol. 9, no. 1, pp. 5-13, 2004.
64. T. Horii, D. Tamura, S. Morita, M. Kimura, and I. Hatada, "Generation of an ICF syndrome model by efficient genome editing of human induced pluripotent stem cells using the CRISPR system, " International Journal of Molecular Sciences, vol. 14, no. 10, pp. 19774-19781, 2013.
65. S. H. Chiou, I. P. Winters, J. Wang et al., "Pancreatic cancer modeling using retrograde viral vector delivery and in vivo CRISPR/Cas9-mediated somatic genome editing, " Genes &Development, vol. 29, no. 14, pp. 1576-1585, 2015.
66. F. Xie, L. Ye, J. C. Chang et al., "Seamless gene correction of -thalassemia mutations in patient-specific iPSCs using CRISPR/Cas9 and piggyBac, " Genome Research, vol. 24, no. 9, pp. 1526-1533, 2014.
67. B. Song, Y. Fan, W. He et al., "Improved hematopoietic differentiation efficiency of gene-corrected beta-thalassemia induced pluripotent stem cells by CRISPR/Cas9 system, " Stem Cells and Development, vol. 24, no. 9, pp. 1053-1065, 2015.
68. C. Y. Park, D. H. Kim, J. S. Son et al., "Functional correction of large factor VIII gene chromosomal inversions in hemophilia a patient-derived iPSCs using CRISPR-Cas9, " Cell Stem Cell, vol. 17, no. 2, pp. 213-220, 2015.